ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab

Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastatic melanoma patients treated with bevacizumab. Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Forthun, Rakel Brendsdal, Hovland, Randi, Schuster, Cornelia, Puntervoll, Hanne, Brodal, Hans Petter, Namløs, Heidi Maria, Aasheim, Lars Birger, Meza-Zepeda, Leonardo A., Gjertsen, Bjørn Tore, Knappskog, Stian, Straume, Oddbjørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877652/
https://www.ncbi.nlm.nih.gov/pubmed/31767937
http://dx.doi.org/10.1038/s41598-019-53917-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877652/
https://www.ncbi.nlm.nih.gov/pubmed/31767937
http://dx.doi.org/10.1038/s41598-019-53917-5

Ejemplares similares